Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising ... to file for approval of Dupixent (dupilumab) in the new indication ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024. 14 Atopic dermatitis is a common ...

Considering taking supplements to treat prurigo nodularis? Below is a list of common natural remedies used to treat or reduce the symptoms of prurigo nodularis. Follow the links to read common ...

EADV 2024 Late Dupilumab Responders Have Unique Molecular ... Medscape Medical News, October 08, 2024 EADV 2024 New Drug Class for Prurigo Nodularis Moving Forward Two years after the first ...

The candidate has demonstrated dupilumab-like activity and very ... chronic spontaneous urticaria and prurigo nodularis, among others. Kymera expects to complete this phase I study and report ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to ...

Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising ... to file for approval of Dupixent (dupilumab) in the new indication ...